MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2019 International Congress

    The effect of levodopa on speech in advanced Parkinson’s Disease: acoustic analysis and correlation with motor features and dyskinesia

    F. Cavallieri, C. Budriesi, A. Gessani, V. Fioravanti, E. Menozzi, S. Contardi, F. Valzania, F. Antonelli (Reggio Emilia, Italy)

    Objective: Analyse the effects of levodopa on speech and its possible relationship with motor features and dyskinesias in a group of advanced Parkinson’s disease (PD)…
  • 2019 International Congress

    High cost of medications for Parkinson’s Disease patients in a rural population of Gujarat, India

    A. Pandya, E. Albert-Stone, A. Deb, S. Desai (Worcester, MA, USA)

    Objective: To understand the economic burden of the cost of Parkinson’s Disease (PD) medications for outpatients receiving care at Shree Krishna Hospital (SKH)  in Karamsad,…
  • 2019 International Congress

    Levodopa Effects on Visuospatial Working Memory in Parkinson’s Disease

    E. Bayram, I. Litvan, B. Wright, C. Grembowski, D. Harrington (La Jolla, CA, USA)

    Objective: To investigate the effects of levodopa on memory load and distractor resistance during visuospatial working memory (WM) in Parkinson’s disease (PD). Background: Visuospatial WM…
  • 2018 International Congress

    Future doctors as health educators: Undergraduate medical students raise awareness and unite for Parkinson’s disease

    S. El-Jaafary, H. Amer, A. Fouad, B. Tawfiq, L. El Sabbahy, A. Bayoumy, B. Abulkarim, B. Gamal, H. Nafea, H. Shehata, M. El-Tamawy (Cairo, Egypt)

    Objective: To highlight the role of undergraduate students in raising the awareness about Parkinson's disease among peers and public. Encouraging the students to take responsibility…
  • 2018 International Congress

    The Interface of advanced therapies as Parkinson’s disease progresses – case reports

    C. Liang, S. Williams, L. Jones, C. Sue, P. Silberstein (St Leonards, Australia)

    Objective: To explore the practical benefits and challenges of adding duodenal levodopa-carbidopa intestinal gel infusion (LCIG) to subthalamic nucleus deep brain stimulation (STN DBS) in…
  • 2018 International Congress

    Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson’s Disease

    J. Boyd, C. Zadikoff, M. Siddiqui, J. Benesh, J. Zamudio, W. Robieson, P. Kukreja (Burlington, VT, USA)

    Objective: Evaluate efficacy/safety of levodopa-carbidopa intestinal gel (LCIG) daytime monotherapy (with/without nighttime oral carbidopa/levodopa) vs polytherapy (LCIG with >1 adjunctive therapy) in advanced Parkinson’s disease…
  • 2018 International Congress

    Patient’s Choice of Device-Based Treatments in Parkinson’s Disease

    M. Kuzu Kumcu, S. Tezcan Aydemir, Ç. Ulukan, B. Bakırarar, C. Akbostancı (Ankara, Turkey)

    Objective: Deep brain stimulation of subtalamic nucleus (STN-DBS), subcutaneous apomorphine infusion (APO) and levodopa-carbidopa intestinal gel infusion (DUO) is routinely used in patients with advanced…
  • 2018 International Congress

    Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease

    I. Mironova, A. Latypova, I. Zhukova, O. Izhboldina, E. Kolupaeva, N. Zhukova, S. Ivanova (Tomsk, Russian Federation)

    Objective: We aimed to study the association between glutamatergic system gene polymorphisms (SLC1A2 – gene, coding excitatory acids transporter, and GRIN2A gene, coding a subunit…
  • 2018 International Congress

    Long Term Response to L-dopa in Parkinson Disease

    H. Gupta, N. Wachter, K. Lyons, R. Pahwa (Kansas, KS, USA)

    Objective: To assess the long-term effectiveness of levodopa in Parkinson’s disease (PD) patients. Background: To date, levodopa continues to be the most efficacious drug in…
  • 2018 International Congress

    Treatment with levodopa/carbidopa intestinal gel of advanced Parkinson’s disease patients: Bulgarian experience

    E. Chorbadzhieva (Sofia, Bulgaria)

    Objective: To evaluate the efficacy of levodopa/carbidopa intestinal gel (LCIG) on motor fluctuations, dyskinesia, parkinson symptoms and quality of life in patients with late Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley